Executive Summary as of October 14, 2010
EXECUTIVE MANAGEMENT
John C. Houghton
President and CEO
• Stryker Biotech – Global Head
Sales and Marketing
• Prior experience with
Lederle/Wyeth, Rhone-
Poulenc, Aventis
Mark Houser, MD, MBA
Chief Medical Officer
• Practicing Nephrologist –
sixteen years
• J&J (Ortho Biotech) - Clinical,
medical affairs and business
development
Brian Lenz, CPA, MBA
Chief Financial Officer
• Public and private company
CFO experience
• VioQuest Pharmaceuticals,
Arno Therapeutics,
KPMG, LLP
BOARD OF DIRECTORS
Russell Ellison, M.D., Chairman
Bami Bastani, PhD
Richard Cohen, CPA, MBA
Gary Gelbfish, M.D.
Timothy Hofer, J.D.
John C. Houghton
Antony Pfaffle, M.D.
SCIENTIFIC ADVISORY BOARD
Joseph Bonventre, M.D. PhD
Z. Ioav Cabantchik, M.D. PhD
Vivian Fonseca, M.D.
Charles Herzog, M.D.
Giuseppe Remuzzi, M.D.
Sudir V. Shah, M.D.
OVERVIEW
CorMedix is a pharmaceutical company that develops and seeks to commercialize therapeutic products
for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. Specifically,
our goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic
complications – in effect, “Treating the kidney to treat the heart.”
INVESTMENT HIGHLIGHTS
• Two product candidates entering late stage clinical development
– Neutrolin for the prevention of central venous catheter (CVC) infection and clotting in
hemodialysis (HD)
– Deferiprone for the prevention of contrast induced nephropathy (CIN) in high-risk patients
• Reduced development and regulatory risk
– Neutrolin: Successful U.S. Pilot study completed; established use in EU markets
– Deferiprone: Available in 50 countries for other indications; approved regulatory path -
special protocol assessment (SPA) with the FDA
• Worldwide commercialization rights
PRODUCT PIPELINE
NEUTROLIN: Prevention of Catheter Related Bloodstream Infections (CRBI)
Market Opportunity
• 80,000 HD catheter patients in the U.S., representing 12.5 million HD sessions per year
(based on 3 sessions per week)
• CVCs are subject to clotting and can result in catheter related bloodstream infection
• Approximately 160,000 CRBI episodes in the U.S. per year1, cost to treat could approach $1 billion2,
6,000 die annually
• No currently approved therapy for CRBI (heparin used for preventing clotting, does not
prevent CRBI)
1
Allon AJKD 51(2):165-168, 2008
2
Manierski Adv Chronic Kidney Dis 13(3):245, 2006
Neutrolin: Overview
• Neutrolin – a catheter lock solution for the prevention of CRBI and maintenance of catheter
function in HD patients
• Contains taurolidine, an anti-microbial
– Prevents infection and formation of biofilm
– No observed bacterial resistance – unlike antibiotics
– >14,000 patients exposed to taurolidine
• Contains citrate and heparin (anti-coagulants) – prevents thrombus formation and clotting
• Safe and well tolerated – no adverse events (AE’s) related to Neutrolin in catheter lock
studies involving ~300 patients
Neutrolin: Demonstrated Effectiveness
Study Number of Average duration Control group % of Neutrolin patients
patients (days) without infection
1 20 pts Neutrolin 85 Heparin 5,000 u/ml 94
30 pts heparin case-control
2 58 158 Heparin 5,000 u/ml 100
3 76 250 None 96
1. Allon M Clin Infect Dis (2003) 36 (12):1539-44
2. Betjes Nephrol Dial Transplant (2004) 19:1546-1551
3. Sodemann K et al Poster: ASN 2001
 Executive Summary as of October 14, 2010
FINANCIAL SUMMARY Neutrolin: Development Plan
June 30, 2010 (000’s) • Pivotal trial expected to commence enrollment 1H11. Prospective, multicenter, double blind,
randomized, active comparator study, ~400 patients, 15 months of duration
Cash $10.6 – Co-primary endpoints: Time to CRBI (superiority); time to all-cause, non-elective catheter
removal (non-inferiority)
Debt None
Neutrolin: Commercialization Plan
• Seek FDA approval for initial U.S. launch in HD indication
Capital structure – Seek to establish Neutrolin as standard of care; inclusion in renal guidelines and dialysis
providers policy and procedure protocols
Common shares 11.4 – Seek quality of care endorsements for improvement in performance criteria in dialysis
Options 1.6 networks
• Apply for CE mark in EU as soon as quality systems in place
Warrants 4.8 • Apply for additional indications for CVCs and Peripherally Inserted Central Catheter (PICC) lines
FD shares O/S 17.8 Neutrolin: IP Overview
• Six (6) issued patents – protection through 2025

Market Cap $16

(As of October 14, 2010) DEFERIPRONE: Prevention of Contrast Induced Nephropathy (CIN)
Market Opportunity
• Cardiac interventions use X-ray and iodinated contrast dye to visualize coronary vessels
STOCK INFORMATION • In “high risk patients” undergoing PCI with Chronic Kidney Disease, the dye can cause kidney
IPO: March 25, 2010 damage - otherwise known as CIN
Exchange/Ticker:
NYSE–Amex/CRMD • CIN is the 3rd most common cause of hospital acquired renal insufficiency
• CIN consequences go beyond kidney damage, including mortality and significant morbidity
• No FDA approved or near-term pharmaceutical therapies
ANALYST COVERAGE Deferiprone: Overview
Griffin Securities • Launched in 1999, available in >50 countries for the treatment of Thalassemia Major
Chrystyna Bedrij, Director Research • Efficacy and safety is well characterized - several thousand patients treated
(212) 509-9500 • In-licensed unique method of use and formulation patents for deferiprone in CKD
cbedrij@griffinsecurities.com
Maxim Group, LLC Deferiprone: Development Plan
Yale Jen, PhD, Vice President • 2Q10: Initiated biomarker Phase II proof of concept trial – Double-blind, placebo controlled
(212) 895-3516 • SPA agreement with the FDA for a single 800 patient pivotal trial for registration (clinical end-
yjen@maximgrp.com points)
National Securities • Seek to engage a partner in Europe
Jason Kolbert, Managing Director
Health Care Research Deferiprone: IP Overview
(212) 417-8287 • Specific CIN patent under prosecution
jkolbert@nationalsecurities.com • 8 issued CKD patents
• Anticipate Hatch Waxman 5 year marketing exclusivity for first approval of deferiprone in U.S.
COMPANY CONTACT ANTICIPATED 2010 MILESTONES & ACHIEVEMENTS
Brian Lenz, CFO
(908) 517-9486 2Q10 Neutrolin Issuance of heparin patent

blenz@cormedix.com
Deferiprone Start Phase II CIN study

Corporate Added to Russell Microcap® Index

CorMedix Inc. 2H10 Urine Catalytic Iron Test Start assay development and validation
745 Route 202-206, Ste 303 Thixotropic Gel Start preclinical studies
Bridgewater, NJ 08807
(908) 517-9486 Deferiprone Interim analysis – Phase II CIN study
www.cormedix.com
Neutrolin Commence application process for CE mark in EU
Neutrolin IDE Submission

This executive summary contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about
our beliefs and expectations regarding results of our clinical trials, development timelines for our product candidates and future events, are forward-looking statements. These statements are not guarantees of future
performance and involve risks, uncertainties and assumptions that are difficult to predict. Pharmaceutical development inherently involves significant risks and uncertainties, including the risks outlined under “Risk
Factors” and elsewhere in our prospectus filed with the Securities and Exchange Commission on March 26, 2010 pursuant to Rule 424(b). Our actual results may differ materially from our expectations due to these
risks and uncertainties, including our dependence on the success of our lead product candidates, and factors relating to regulatory approval, research and development, intellectual property protection, competition,
industry environment, ability to raise sufficient capital and other matters. Any forward-looking statements included in this executive summary are based on information available to us on the date of this executive
summary. Except for our ongoing obligations to disclose material information under the federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report
events or to report the occurrence of unanticipated events.